Fulcrum Therapeutics Inc. (FULC) shares surged Monday after the company released results from its Phase 1b PIONEER trial that suggest higher doses of its experimental sickle cell treatment might deliver meaningfully better outcomes.
The biotech is testing pociredir, and the latest data from the 20 mg dose cohort shows what CEO Alex Sapir called "clear evidence of a dose-response." Here's what that actually means: patients on the higher dose saw bigger improvements faster than those on the lower 12 mg dose the company tested earlier.
The Numbers That Matter
Mean absolute fetal hemoglobin (HbF) increased by 9.9% at six weeks of treatment with the 20 mg dose. That compares favorably to 5.6% at week six and 8.6% at week 12 in the earlier 12 mg cohort. Patients started with a baseline HbF of 7.1% and reached 16.9% by week six.
Why does fetal hemoglobin matter? In sickle cell disease, boosting HbF levels can dramatically reduce the painful vaso-occlusive crises that define the condition. And the results here look promising: as of the November 11, 2025 data cutoff, seven of 12 patients (58%) achieved absolute HbF levels of 20% or higher at week six. All patients showed robust HbF increases.
That 20% threshold is particularly important. Based on real-world data Fulcrum presented at the Annual Sickle Cell & Thalassemia Conference in October, HbF levels of 20% are associated with roughly 90% of patients experiencing zero vaso-occlusive crises per year.
The Dose-Response Story
Among the six patients who reached the week 12 visit by the data cutoff, pociredir induced a greater than 3.75-fold mean increase in HbF, compared to a 2.4-fold mean induction at week 12 in the 12 mg cohort. The average baseline for these six patients was 5% compared to 7.1% for the full cohort, which is why fold induction matters—it accounts for baseline differences and enables normalized dose-response comparisons.
The proportion of F-cells (red blood cells containing HbF) increased from a mean of 31% at baseline to 58% at week six, indicating early progression toward pan-cellular HbF induction, meaning the fetal hemoglobin is being distributed more evenly across red blood cells.
On the safety front, the 20 mg dose cohort showed a profile consistent with previously reported data from the 12 mg cohort, which is what you want to see when you're escalating doses.
Wall Street Weighs In
Analysts responded with enthusiasm and raised price targets across the board. HC Wainwright maintains a Buy rating and lifted its price forecast from $18 to $25. Piper Sandler reiterated Overweight and raised its target from $16 to $23. Cantor Fitzgerald maintained Overweight and bumped its target from $15 to $24. Even RBC Capital, which holds a more cautious Sector Perform rating, raised its price forecast from $7 to $10.
Fulcrum shares were trading up 9.66% at $14.21 on Monday.
